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OBJECTIVES We hypothesized that elevated B-type natriuretic peptide (BNP) levels would be associated
with a greater severity of angiographic disease and a greater extent of myocardium at risk.
BACKGROUND Elevations of BNP have been associated with increased risk of adverse outcomes in patients
with unstable angina and non–ST-segment elevation myocardial infarction (UA/NSTEMI).
METHODS Of the 2,220 patients with UA/NSTEMI enrolled in the Treat Angina with Aggrastat and
Determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis In
Myocardial Infarction-18 (TACTICS–TIMI-18) trial, 276 randomized to the invasive arm
had both baseline BNP levels and angiographic core laboratory data. Patients were
categorized according to their baseline BNP levels as 80 or 80 pg/ml.
RESULTS A total of 233 patients (84%) had BNP levels 80 pg/ml, and 43 (16%) had admission BNP
levels 80 pg/ml. Patients with BNP 80 pg/ml had tighter culprit vessel stenosis on
quantitative coronary angiography (median stenosis 76% vs. 67%, p  0.004) and a higher
(slower) corrected TIMI frame count (median CTFC 43 vs. 30, p  0.018) in the culprit
vessel. The median BNP level was higher in patients with a left anterior descending coronary
artery (LAD) versus non-LAD culprit lesion location (median BNP level 40 vs. 24 pg/ml, p
 0.005), and the culprit artery was more often the LAD in patients with BNP 80 pg/ml
compared with 80 pg/ml (44% vs. 30%, p  0.06).
CONCLUSIONS Among patients with UA/NSTEMI, elevated BNP levels are associated with tighter culprit
stenosis, higher CTFC, and LAD involvement. These findings suggest that elevated BNP
may be associated with a greater severity and extent of myocardial ischemic territory during
the index event and may partly explain the association between elevated BNP and adverse
outcomes. (J Am Coll Cardiol 2004;44:564–8) © 2004 by the American College of
Cardiology Foundationi
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s-type natriuretic peptide (BNP) is a peptide hormone
eleased from cardiac ventricles in response to myocardial
tretch or increased wall tension (1). The diagnostic and
rognostic significance of elevated BNP in patients with
eart failure has been well studied (2,3). In patients with
T-segment elevation myocardial infarction (STEMI), el-
vated levels of BNP are associated with a larger infarct size,
rogressive left ventricular (LV) remodeling, and increased
ortality (4–9). Several studies have also demonstrated a
trong association between elevated BNP levels and an
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epartment of Medicine, Harvard Medical School, Boston, Massachusetts; ‡Merck
Co., West Point, Pennsylvania; and §Donald W. Reynolds Cardiovascular Clinical
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he TACTICS–TIMI-18 trial was funded by Merck & Co. Drs. de Lemos and
orrow have received grant support from Biosite Inc., San Diego, California, the
anufacturers of the Triage BNP test.
Manuscript received January 16, 2004; revised manuscript received March 24,o004, accepted March 29, 2004.ncreased incidence of adverse outcomes in patients with
nstable angina and non–ST-elevation myocardial infarc-
ion (UA/NSTEMI) (10–16). This association was incre-
ental to the prognostic information provided by elevated
ardiac troponin levels (13). However, the underlying
athophysiologic mechanisms responsible for this associa-
ion between BNP and outcome have not been well defined.
e tested the hypothesis that elevated BNP levels in
atients with UA/NSTEMI would be associated with more
evere coronary vascular disease and greater abnormalities in
oronary blood flow.
ETHODS
tudy population. The study population was derived from
he UA/NSTEMI patients enrolled in the Treat Angina
ith Aggrastat and Determine Cost of Therapy with an
nvasive or Conservative Strategy–Thrombolysis In Myo-
ardial Infarction-18 (TACTICS–TIMI-18) trial, the re-
ults of which have been previously published (17). A total
f 2,220 patients with UA/NSTEMI were randomly as-
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August 4, 2004:564–8 Angiographic Correlation of BNP in UA/NSTEMIigned to either an early invasive strategy that included
outine cardiac catheterization within 4 to 48 h and revas-
ularization, as appropriate, or a conservative strategy in
hich cardiac catheterization was performed only if the
atient had objective evidence of recurrent ischemia or an
bnormal stress test. All patients received aspirin, heparin,
nd tirofiban. The primary end point was a composite of
eath, nonfatal re-infarction, and repeat hospitalization for
cute coronary syndromes at six months. For the purpose of
his study, patients who were randomized to the early
nvasive strategy and who also had admission BNP levels
nd core laboratory angiographic data were selected for
nalysis. We excluded patients randomized to the conser-
ative strategy, as they did not undergo routine early
oronary angiography. Eligible patients were categorized
nto two groups based on their admission BNP levels of
80 or 80 pg/ml. The clinical and core laboratory
ngiographic characteristics of the two groups were
ompared.
esting of BNP. In the TACTICS–TIMI-18 trial, blood
amples were collected at the time of enrollment, according
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CAD  coronary artery disease
CTFC  corrected TIMI frame count
LAD  left anterior descending
coronary artery
LV  left ventricular
NSTEMI  non–ST-segment elevation
myocardial infarction
STEMI  ST-segment elevation
myocardial infarction
TACTICS–TIMI-18  Treat Angina with Aggrastat
and Determine Cost of Therapy
with an Invasive or
Conservative
Strategy–Thrombolysis In
Myocardial Infarction-18 trial
UA  unstable angina
Table 1. Baseline Clinical Characteristics by B
Characteristics
BNP
(n
Median age (yrs) 61
Male gender (%)
Hypertension (%)
Diabetes (%)
Smoking (%)
Hyperlipidemia (%)
Previous MI (%)
Previous PTCA (%)
History of previous angina (%)
ST-segment deviation 0.5 mm (%)
T-wave changes (%)
Index event NSTEMI (%)
*Median 22 (25th, 75th percentiles of 3, 41) pg/ml. †Media
BNP  B-type natriuretic peptide; MI  myocardialinfarction; PTCA  percutaneous transluminal coronary angioplaso the protocol, in citrate-anticoagulated tubes and plasma
solated within 60 min of sample collection. Aliquots of the
amples were shipped frozen to Biosite Inc. (San Diego,
alifornia), where they were thawed and analyzed using an
stablished immunoassay by personnel blinded to the study
etails. The primary decision limit of 80 pg/ml was pre-
pecified based on previous work with this assay (12,13).
ngiographic analysis. At centers participating in the
ngiographic substudy, all coronary angiograms of patients
ndergoing cardiac catheterization and/or percutaneous
oronary intervention were evaluated at the TIMI angio-
raphic core laboratory by physicians who were blinded to
he patient’s clinical or BNP status. Coronary stenoses were
uantified using validated quantitative coronary angiogra-
hy. Assessment of epicardial coronary flow was done using
he TIMI flow grade and corrected TIMI frame count
CTFC), according to previously described methods
18,19). The presence of thrombus was assessed by visual
stimation.
tatistical methods. Variables were compared using the
hi-square test for categorical data. Continuous data are
eported as the median value and interquartile range. The
onparametric Wilcoxon rank-sum test was used for the
nalysis of continuous variables.
ESULTS
f the 2,220 patients from the TACTICS–TIMI-18
rial, 1,114 were randomized to early invasive strategy.
verall, 276 patients had both core laboratory angio-
raphic data and BNP levels at randomization. Of these,
33 patients (84%) had BNP levels 80 pg/ml and 43
atients (16%) had BNP level 80 pg/ml. The median
25th, 75th percentile) BNP levels of the two groups were
2 (3, 41) and 137 (95, 173) pg/ml, respectively. The
aseline clinical characteristics of the patients in both
roups are shown in Table 1. Patients with BNP 80
g/ml were older (median age 67 [60, 73] vs. 61 [53, 70]
ears, p  0.007) and were more likely to have NSTEMI
e Natriuretic Peptide Groups
pg/ml*
33)
BNP >80 pg/ml†
(n  43) p Value
70) 67 (60, 73) 0.007
56 0.14
74 0.15
28 0.39
21 0.22
47 0.02
47 0.26
30 0.68
14 0.8
42 0.43
44 0.11
60 0.008
(95, 173) pg/ml.
tion; NSTEMI  non–ST-segment elevation myocardial-Typ
<80
 2
(53,
67
63
22
30
65
37
33
15
36
32
39
n 137
infarcty.
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Angiographic Correlation of BNP in UA/NSTEMI August 4, 2004:564–8s the index event at randomization (60% vs. 39%, p 
.008). They also had a lower prevalence of hyperlipid-
mia (47% vs. 65%, p  0.02), but the populations were
therwise similar.
A BNP level 80 pg/ml was associated with tighter
ulprit vessel diameter stenoses (median stenosis 76% vs.
8%, p 0.004) and higher CTFCs (i.e., slower flow in the
ulprit artery) (median CTFC 43 vs. 30, p  0.018) (Table
). The median BNP level was higher among patients with
left anterior descending coronary artery (LAD) compared
ith a non-LAD culprit lesion location (median BNP level
0 vs. 24 pg/ml, p  0.005). Among patients with an LAD
ulprit lesion, a proximal/mid-LAD culprit lesion location
as associated with higher BNP levels, as compared with a
istal LAD lesion location (median BNP level 41 vs. 10
g/ml, p  0.005) (Fig. 1). In addition, the median BNP
evel was higher in patients with thrombus, three-vessel
isease, or TIMI flow grade 0 or 1 (median BNP 34 vs. 23
g/ml, p  0.048). The association of elevated BNP with
everity of stenosis, higher CTFC, and LAD culprit lesion
ocation remained significant even after adjusting for age
nd index event NSTEMI (p  0.05 for each).
Table 2. Baseline Angiographic Characteristics
Angiographic Characteristics
BNP <80
(n  2
Median stenosis (%) 68 (57,
Median CTFC 30 (22,
TIMI flow grade 0/1 (%) 10
Thrombus (%) 36
3-Vessel disease (%) 18
LAD culprit artery (%) 30
Data are presented as the median value (25th, 75th percenti
BNP  B-type natriuretic peptide; CTFC  corrected T
TIMI  Thrombolysis In Myocardial Infarction.
igure 1. Median B-type natriuretic peptide (BNP) levels in patients with
n left anterior descending coronary artery (LAD) versus non-LAD culprit
esion location and proximal/mid-LAD location versus distal culprit lesionoocation.ISCUSSION
mong patients with UA/NSTEMI, elevated BNP is
ssociated with tighter culprit lesion diameter stenoses, a
igher CTFC (slower flow in culprit artery), and an LAD
nd more proximal culprit lesion location.
Several studies have evaluated the clinical significance of
levated BNP in patients with UA/NSTEMI (12–16). In
he Oral Glycoprotein IIb/IIIa Inhibition with Orbofiban in
atients with Unstable Coronary Syndromes–Thrombolysis
n Myocardial Infarction-16 (OPUS–TIMI-16) trial, ele-
ated BNP measured at a mean time of 40  20 h after the
nset of symptoms was associated with a high risk of death,
yocardial infarction, and heart failure at 30 days and 10
onths (12). This association remained significant for the
ubgroup of patients with UA/NSTEMI. Furthermore,
fter adjustment for other independent predictors of the
ong-term risk of death, BNP 80 pg/ml was significantly
ssociated with increased mortality at 10 months. Moreover,
atients with BNP 80 pg/ml were also at a high risk of
ew or progressive heart failure, as compared with patients
ith BNP 80 pg/ml. In the TACTICS–TIMI-18 trial,
A/NSTEMI patients with BNP80 pg/ml at enrollment
ad a higher mortality at seven days and six months. The
ssociation between elevated BNP and increased mortality
as independent of other important clinical predictors,
ncluding elevated troponin I and heart failure (13).
-terminal pro-BNP (the amino terminal portion of the
ro-hormone pro-BNP) has also been shown to have
imilar prognostic significance in patients with UA/
STEMI (14–16). Jernberg et al. (14) studied 755 patients
ith UA/NSTEMI who had N-terminal pro-BNP mea-
ured on admission. During a median follow-up of 40
onths, patients with elevated N-terminal pro-BNP had a
igher mortality independent of clinical features, electrocar-
iographic changes, and troponin levels. Similar results were
btained by Omland et al. (15), who showed that elevated
-terminal pro-BNP was a powerful indicator of long-term
ortality independent of age, Killip class, and LV ejection
raction. James et al. (16) studied 6,809 patients with
A/NSTEMI enrolled in the Global Utilization of Strat-
gies To Open occluded arteries IV (GUSTO-IV) trial,
ho had N-terminal pro-BNP measured at a median time
-Type Natriuretic Peptide Groups
l BNP >80 pg/ml
(n  43) p Value
76 (66, 84) 0.004
43 (26, 100) 0.018
19 0.13
45 0.23
26 0.34
44 0.06
percentage of patients.
ame count; LAD  left anterior descending coronary artery;by B
pg/m
33)
76)
46)
le) or
IMI frf 9.5 h after symptom onset. In this study, increasing
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August 4, 2004:564–8 Angiographic Correlation of BNP in UA/NSTEMIuartiles of N-terminal pro-BNP were independently asso-
iated with both short- and long-term mortality.
Despite the growing body of evidence demonstrating a
trong association between elevated BNP in patients with
A/NSTEMI and increased risk of adverse outcomes, the
nderlying pathophysiologic mechanisms responsible for
his adverse association are not well defined. Because BNP
s released in response to increased intraventricular pressure
r wall tension, in UA/NSTEMI patients with manifest
eart failure or a decreased LV ejection fraction, elevated
NP reflects a greater degree of myocardial dysfunction and
ence, not surprisingly, is associated with a greater risk of
eath and recurrent congestive heart failure. However, the
ssociation between elevated BNP and increased risk of
dverse outcomes appears to be independent of heart failure
r LV ejection fraction (12,13,15). Thus, mechanisms other
han LV dysfunction may also play a role (20,21).
Several observations have suggested that elevated BNP
ay be a marker of the extent and severity of ischemia.
atients with proven coronary artery disease (CAD) have
levated BNP levels during dynamic exercise, as compared
ith patients without CAD (22). In a study of 35 patients
ith stable angina and CAD documented on coronary
ngiography and 35 control subjects with normal angio-
rams, plasma levels of BNP increased during thallium
xercise testing in patients with angina and CAD, but did
ot change significantly in the control group. Further, a
reater severity of myocardial perfusion defect on the
hallium perfusion scans correlated with greater plasma
evels of BNP. It has also been demonstrated that transient
schemia induced by percutaneous transluminal coronary
ngioplasty can lead to elevation of BNP even in the absence
f demonstrable changes in LV systolic function or LV
nd-diastolic pressure (23,24). It has been speculated that
schemia may lead to altered regional myocardial stretch,
ausing active secretion of BNP (1).
We have previously shown that elevated BNP levels are
ssociated with multi-vessel CAD (13). The results of this
xtended analysis demonstrate that UA/NSTEMI patients
ith elevated BNP have tighter culprit artery diameter
tenoses, a higher CTFC, and a more LAD and proximal
ulprit lesion location. The tighter stenosis would predis-
ose to more severe ischemia, and the association with a
roximal/mid-LAD culprit lesion location suggests a larger
xtent of ischemia. The higher CTFC in patients with
levated BNP levels is most likely related to the severity of
picardial stenosis. The association of elevations of BNP
ith a greater severity and extent of ischemia may explain,
t least in part, the adverse clinical outcomes of such
levation.
tudy limitations. This is a retrospective subgroup analy-
is. The study population was small; hence, the data should
e interpreted with caution. Assessment of LV function was
ot routinely available. Some of the angiographic findings
ay have been rendered nonsignificant because of the sizef the study population. A prospective study of a larger
opulation is desirable.
onclusions. Elevated BNP in patients with UA/
STEMI is associated with tighter culprit lesion diameter
tenosis, higher (slower) CTFC, as well as an LAD and
roximal culprit lesion location. These results suggest that
levated BNP may be associated with a greater severity and
xtent of myocardial ischemic territory during the index
vent.
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